​

Exelixis (EXEL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EXEL Stock Forecast

Exelixis stock forecast is as follows: an average price target of $30.89 (represents a -7.21% downside from EXEL’s last price of $33.29) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.

EXEL Price Target

The average price target for Exelixis (EXEL) is $30.89 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $18.00. This represents a potential -7.21% downside from EXEL's last price of $33.29.

EXEL Analyst Ratings

Buy

According to 16 Wall Street analysts, Exelixis's rating consensus is 'Buy'. The analyst rating breakdown for EXEL stock is 0 'Strong Buy' (0.00%), 13 'Buy' (81.25%), 2 'Hold' (12.50%), 1 'Sell' (6.25%), and 0 'Strong Sell' (0.00%).

Exelixis Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2024Etzer DaroutBMO Capital$36.00$32.5610.57%8.14%
Oct 30, 2024Asthika GoonewardeneTruist Financial$38.00$28.7332.27%14.15%
Oct 30, 2024Joseph CatanzaroPiper Sandler$36.00$28.7325.30%8.14%
Oct 30, 2024David LebowitzCitigroup$38.00$28.7332.27%14.15%
Oct 16, 2024Christopher LiuLeerink Partners$28.50$28.50--14.39%
Oct 16, 2024Kennen MacKayRBC Capital$34.00$28.5019.30%2.13%
Oct 16, 2024Chris ShibutaniGoldman Sachs$18.00$28.50-36.84%-45.93%
Oct 15, 2024Akash TewariJefferies$33.00$28.8014.60%-0.87%
Oct 15, 2024Jeffrey HungMorgan Stanley$30.00$28.505.26%-9.88%
Oct 14, 2024Asthika GoonewardeneTruist Financial$33.00$26.2425.76%-0.87%
Oct 14, 2024Sudan LoganathanStephens$23.00$26.23-12.33%-30.91%
Oct 11, 2024Jeffrey HungMorgan Stanley$28.00$25.977.82%-15.89%
Sep 19, 2024Ashwani VermaUBS$30.00$26.8211.86%-9.88%
Sep 16, 2024David LebowitzCitigroup$31.00$26.4617.16%-6.88%
Sep 04, 2024Jason GerberryBank of America Securities$30.00$25.4317.95%-9.88%
Aug 08, 2024Robert BurnsH.C. Wainwright$29.00$26.529.35%-12.89%
Aug 07, 2024Silvan TuerkcanJMP Securities$29.00$23.4523.67%-12.89%
May 20, 2024David LebowitzNew Street$31.00$21.0647.20%-6.88%
May 20, 2024George Farmertzer DaroutBMO Capital$29.00$21.0737.67%-12.89%
Apr 11, 2024Peter LawsonBarclays$25.00$23.685.57%-24.90%
Dec 09, 2022JMP Securities$25.00$16.5251.33%-24.90%
Jun 28, 2021Michael SchmidtGuggenheim$30.00$18.0266.48%-9.88%
May 18, 2021Chris ShibutaniGoldman Sachs$23.00$24.34-5.51%-30.91%
Apr 19, 2021Jeffrey HungMorgan Stanley$26.00$23.749.52%-21.90%

The latest Exelixis stock forecast, released on Oct 30, 2024 by Etzer Darout from BMO Capital, set a price target of $36.00, which represents a 10.57% increase from the stock price at the time of the forecast ($32.56), and a 8.14% increase from EXEL last price ($33.29).

Exelixis Price Target by Period

1M3M12M
# Anlaysts-1320
Avg Price Target-$31.19$30.48
Last Closing Price$33.29$33.29$33.29
Upside/Downside-100.00%-6.31%-8.44%

In the current month, the average price target of Exelixis stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Exelixis's last price of $33.29. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024GuggenheimBuyBuyHold
Oct 30, 2024Piper SandlerOverweightOverweightHold
Oct 21, 2024RBC CapitalUnderperformUnderperformHold
Oct 16, 2024Leerink PartnersMarket PerformMarket PerformHold
Oct 16, 2024RBC CapitalOutperformOutperformHold
Oct 16, 2024Goldman SachsSellSellHold
Oct 15, 2024JefferiesBuyBuyHold
Oct 15, 2024Cowen & Co.BuyBuyHold
Oct 15, 2024BMO CapitalOutperformOutperformHold
Oct 15, 2024Morgan StanleyPositivePositiveHold
Oct 14, 2024StephensEqual-WeightEqual-WeightHold
Oct 14, 2024CitigroupBuyBuyHold
Oct 11, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Oct 07, 2024Zacks Investment ResearchOutperformOutperformHold
Oct 04, 2024UBSBuyBuyHold
Sep 19, 2024UBSNeutralInitialise
Sep 18, 2024OppenheimerUnderperformUnderperformHold
Sep 18, 2024RBC CapitalMarket OutperformMarket OutperformHold
Sep 16, 2024H.C. WainwrightBuyBuyHold
Sep 16, 2024CitigroupBuyBuyHold
Sep 04, 2024Bank of America SecuritiesBuyBuyHold
Aug 08, 2024StephensMarket OutperformMarket OutperformHold
Aug 08, 2024RBC CapitalUnderperformUnderperformHold
Aug 08, 2024H.C. WainwrightBuyBuyHold
Aug 07, 2024JMP SecuritiesOutperformOutperformHold
May 20, 2024CitigroupBuyBuyHold
May 20, 2024BMO CapitalOutperformOutperformHold
May 13, 2024StephensEqual-WeightInitialise
May 01, 2024Cowen & Co.BuyBuyHold
Jan 30, 2024RBC CapitalMarket OutperformMarket OutperformHold
Jan 30, 2024Morgan StanleyUnderperformUnderperformHold
Jan 08, 2024William BlairOutperformOutperformHold
Feb 08, 2023Piper SandlerOverweightOverweightHold
Dec 09, 2022JMP SecuritiesMarket OutperformMarket OutperformHold

Exelixis's last stock rating was published by Guggenheim on Oct 30, 2024. The company gave EXEL a "Buy" rating, the same as its previous rate.

Exelixis Financial Forecast

Exelixis Revenue Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Revenue----------------$479.65M$471.92M$469.85M$408.79M$423.92M$411.74M$419.43M$355.98M$451.14M$328.42M$385.18M$270.23M$270.05M$231.09M
Avg Forecast$754.20M$727.10M$690.20M$613.90M$605.10M$572.90M$552.60M$508.00M$575.43M$556.12M$527.64M$496.68M$556.38M$490.31M$465.47M$461.04M$480.33M$473.48M$446.29M$422.66M$417.61M$403.47M$391.03M$374.45M$355.78M$358.58M$300.03M$266.56M$270.00M$214.67M
High Forecast$776.66M$748.75M$710.75M$632.18M$623.12M$589.96M$569.06M$523.13M$592.56M$572.68M$543.35M$506.19M$580.02M$491.49M$465.47M$461.04M$514.18M$497.32M$459.58M$435.24M$430.04M$403.47M$391.03M$374.45M$355.78M$358.58M$300.03M$266.56M$270.00M$214.67M
Low Forecast$732.38M$706.06M$670.23M$596.14M$587.59M$556.33M$536.61M$493.30M$558.78M$540.03M$512.37M$491.54M$497.75M$489.12M$465.47M$461.04M$449.25M$446.19M$433.38M$410.43M$405.53M$403.47M$391.03M$374.45M$355.78M$358.58M$300.03M$266.56M$270.00M$214.67M
# Analysts222222221115121066101577101111117777713
Surprise %----------------1.00%1.00%1.05%0.97%1.02%1.02%1.07%0.95%1.27%0.92%1.28%1.01%1.00%1.08%

Exelixis's average Quarter revenue forecast for Mar 24 based on 6 analysts is $461.04M, with a low forecast of $461.04M, and a high forecast of $461.04M. EXEL's average Quarter revenue forecast represents a -3.88% decrease compared to the company's last Quarter revenue of $479.65M (Dec 23).

Exelixis EBITDA Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts222222221115121066101577101111117777713
EBITDA----------------$88.31M$-17.58M$77.85M$28.83M$-48.08M$88.28M$88.48M$83.24M$119.95M$58.06M$128.56M$1.21M$30.54M$-35.67M
Avg Forecast$142.99M$137.85M$130.85M$116.39M$114.72M$108.61M$104.77M$96.31M$109.09M$105.43M$100.03M$94.16M$105.48M$92.96M$88.25M$70.06M$91.06M$89.76M$84.61M$63.69M$254.47M$74.68M$72.38M$50.35M$65.85M$66.37M$55.53M$1.82M$49.98M$39.73M
High Forecast$147.24M$141.95M$134.75M$119.85M$118.13M$111.85M$107.89M$99.18M$112.34M$108.57M$103.01M$95.97M$109.96M$93.18M$88.25M$84.07M$97.48M$94.29M$87.13M$76.43M$305.36M$74.68M$72.38M$60.42M$65.85M$66.37M$55.53M$2.18M$49.98M$39.73M
Low Forecast$138.85M$133.86M$127.07M$113.02M$111.40M$105.47M$101.73M$93.52M$105.94M$102.38M$97.14M$93.19M$94.37M$92.73M$88.25M$56.05M$85.17M$84.59M$82.16M$50.95M$203.58M$74.68M$72.38M$40.28M$65.85M$66.37M$55.53M$1.45M$49.98M$39.73M
Surprise %----------------0.97%-0.20%0.92%0.45%-0.19%1.18%1.22%1.65%1.82%0.87%2.31%0.67%0.61%-0.90%

6 analysts predict EXEL's average Quarter EBITDA for Mar 24 to be $70.06M, with a high of $84.07M and a low of $56.05M. This is -20.67% lower than Exelixis's previous annual EBITDA (Dec 23) of $88.31M.

Exelixis Net Income Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts222222221115121066101577101111117777713
Net Income----------------$85.52M$1.04M$81.18M$40.03M$-30.17M$73.21M$70.67M$68.57M$95.17M$38.20M$96.09M$1.60M$28.39M$-32.04M
Avg Forecast----$198.23M$185.64M$173.14M$148.74M$123.48M$126.88M$110.77M$98.11M$113.60M$98.90M$90.31M$52.48M$66.45M$28.54M$44.89M$47.71M$201.89M$56.31M$57.82M$37.72M$17.93M$57.46M$17.88M$2.40M$16.84M$2.94M
High Forecast----$205.91M$192.83M$179.84M$154.50M$128.26M$131.79M$115.06M$105.29M$143.23M$99.00M$90.33M$62.98M$77.17M$51.38M$46.62M$57.25M$242.27M$56.31M$57.82M$45.26M$17.93M$57.46M$17.88M$2.88M$16.84M$2.94M
Low Forecast----$190.78M$178.66M$166.63M$143.15M$118.84M$122.11M$106.61M$95.72M$61.74M$98.81M$90.29M$41.98M$53.59M$-24.74M$43.20M$38.17M$161.51M$56.31M$57.82M$30.17M$17.93M$57.46M$17.88M$1.92M$16.84M$2.94M
Surprise %----------------1.29%0.04%1.81%0.84%-0.15%1.30%1.22%1.82%5.31%0.66%5.37%0.67%1.69%-10.90%

Exelixis's average Quarter net income forecast for Mar 24 is $52.48M, with a range of $41.98M to $62.98M. EXEL's average Quarter net income forecast represents a -38.63% decrease compared to the company's last Quarter net income of $85.52M (Dec 23).

Exelixis SG&A Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts222222221115121066101577101111117777713
SG&A----------------$131.44M$138.14M$141.72M$131.40M$119.25M$114.98M$122.76M$102.86M$99.31M$101.56M$98.50M$102.35M$82.44M$88.19M
Avg Forecast$210.39M$202.83M$192.54M$171.25M$168.80M$159.82M$154.15M$141.71M$160.52M$155.14M$147.19M$138.55M$155.21M$136.78M$129.85M$78.72M$133.99M$132.08M$124.50M$71.57M$210.68M$112.55M$109.08M$56.57M$99.25M$100.03M$83.70M$153.53M$75.32M$59.88M
High Forecast$216.66M$208.87M$198.27M$176.35M$173.83M$164.58M$158.74M$145.93M$165.30M$159.76M$151.57M$141.21M$161.80M$137.11M$129.85M$94.47M$143.44M$138.73M$128.21M$85.88M$252.82M$112.55M$109.08M$67.89M$99.25M$100.03M$83.70M$184.23M$75.32M$59.88M
Low Forecast$204.31M$196.97M$186.97M$166.30M$163.92M$155.19M$149.69M$137.61M$155.88M$150.65M$142.93M$137.12M$138.85M$136.45M$129.85M$62.98M$125.32M$124.47M$120.90M$57.25M$168.54M$112.55M$109.08M$45.26M$99.25M$100.03M$83.70M$122.82M$75.32M$59.88M
Surprise %----------------0.98%1.05%1.14%1.84%0.57%1.02%1.13%1.82%1.00%1.02%1.18%0.67%1.09%1.47%

Exelixis's average Quarter SG&A projection for Mar 24 is $78.72M, based on 6 Wall Street analysts, with a range of $62.98M to $94.47M. The forecast indicates a -40.11% fall compared to EXEL last annual SG&A of $131.44M (Dec 23).

Exelixis EPS Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts222222221115121066101577101111117777713
EPS------------------$0.25$0.12$-0.09$0.23$0.22$0.21$0.30$0.12$0.31$0.01$0.09$-0.10
Avg Forecast----$0.68$0.64$0.59$0.51$0.42$0.44$0.38$0.34$0.39$0.34$0.31$0.22$0.23$0.10$0.15$0.16$-0.11$0.19$0.20$0.14$0.06$0.20$0.06$0.03$0.06$0.01
High Forecast----$0.71$0.66$0.62$0.53$0.44$0.45$0.39$0.36$0.49$0.34$0.31$0.23$0.26$0.18$0.16$0.17$-0.11$0.19$0.20$0.14$0.06$0.20$0.06$0.03$0.06$0.01
Low Forecast----$0.65$0.61$0.57$0.49$0.41$0.42$0.37$0.33$0.21$0.34$0.31$0.22$0.18$-0.08$0.15$0.15$-0.11$0.19$0.20$0.14$0.06$0.20$0.06$0.03$0.06$0.01
Surprise %-----------------0.03%1.62%0.75%0.84%1.20%1.12%1.48%4.92%0.61%5.10%0.17%1.57%-10.00%

According to 10 Wall Street analysts, Exelixis's projected average Quarter EPS for Dec 23 is $0.23, with a low estimate of $0.18 and a high estimate of $0.26. This represents a 6808.18% increase compared to EXEL previous annual EPS of - (Sep 23).

Exelixis Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
PDSBPDS Bio$1.96$9.00359.18%Buy
BTAIBioXcel Therapeutics$0.39$1.00156.41%Buy
VKTXViking Therapeutics$46.70$97.80109.42%Buy
SRPTSarepta Therapeutics$125.76$187.2048.85%Buy
BMRNBioMarin Pharmaceutical$67.19$94.4340.54%Buy
ALNYAlnylam Pharmaceuticals$246.58$310.6025.96%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy
KODKodiak Sciences$8.87$11.0024.01%Buy
HALOHalozyme Therapeutics$48.60$52.007.00%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
PTCTPTC Therapeutics$47.02$48.002.08%Hold
EXELExelixis$34.69$30.89-10.95%Buy
TGTXTG Therapeutics$33.57$23.75-29.25%Buy

EXEL Forecast FAQ

Is Exelixis a good buy?

Yes, according to 16 Wall Street analysts, Exelixis (EXEL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 13 'Buy' recommendations, accounting for 81.25% of EXEL's total ratings.

What is EXEL's price target?

Exelixis (EXEL) average price target is $30.89 with a range of $18 to $38, implying a -7.21% from its last price of $33.29. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Exelixis stock go up soon?

According to Wall Street analysts' prediction for EXEL stock, the company can go down by -7.21% (from the last price of $33.29 to the average price target of $30.89), up by 14.15% based on the highest stock price target, and down by -45.93% based on the lowest stock price target.

Can Exelixis stock reach $50?

EXEL's average twelve months analyst stock price target of $30.89 does not support the claim that Exelixis can reach $50 in the near future.

What are Exelixis's analysts' financial forecasts?

Exelixis's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.24B (high $2.31B, low $2.17B), average EBITDA is $424.41M (high $437.05M, low $412.13M), average net income is $705.76M (high $733.08M, low $679.21M), average SG&A $624.48M (high $643.08M, low $606.42M), and average EPS is $2.42 (high $2.52, low $2.33). EXEL's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $2.79B (high $2.87B, low $2.7B), average EBITDA is $528.07M (high $543.8M, low $512.8M), average net income is $0 (high $0, low $0), average SG&A $777.02M (high $800.16M, low $754.54M), and average EPS is $0 (high $0, low $0).

Did the EXEL's actual financial results beat the analysts' financial forecasts?

Based on Exelixis's last annual report (Dec 2023), the company's revenue was $1.83B, beating the average analysts forecast of $1.82B by 0.41%. Apple's EBITDA was $196.6M, missing the average prediction of $329.13M by -40.27%. The company's net income was $207.76M, beating the average estimation of $187.59M by 10.76%. Apple's SG&A was $542.7M, beating the average forecast of $462.14M by 17.43%. Lastly, the company's EPS was $0.65, beating the average prediction of $0.641 by 1.48%. In terms of the last quarterly report (Dec 2023), Exelixis's revenue was $479.65M, missing the average analysts' forecast of $480.33M by -0.14%. The company's EBITDA was $88.31M, missing the average prediction of $91.06M by -3.02%. Exelixis's net income was $85.52M, beating the average estimation of $66.45M by 28.70%. The company's SG&A was $131.44M, missing the average forecast of $133.99M by -1.90%. Lastly, the company's EPS was $0, missing the average prediction of $0.228 by -100.00%